🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

2 Capsule(s) Serving Size
60 Servings
Other Combinations Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

Larch Arabinogalactan
500 mg
Pectin
400 mg
📊 Market median: 600.0mg (7 products) 📚 39 studies (Tier A: 2, B: 13)
This product: 200mg
📊 Market median: 1000.0mg (1115 products) 📚 22 studies (Tier A: 0, B: 9)
This product: 200mg
100 mg
📊 Market median: 1000.0mg (212 products) 📚 12 studies (Tier A: 0, B: 3)
This product: 100mg
Gum Tragacanth
100 mg

Other Ingredients

Cellulose Rice Extract Rice Concentrate

Label Claims — Verification

All Other
Structure/Function
All Other (96% of products) Structure/Function (81% of products) Nutrient (19% of products) No Claim (3% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

Directions: Two (2) capsules 2-3 daily with meals as a dietary supplement or as directed by a physician.

🧪 Formulation Notes

Right for your type B Lectin blocking formula designed for type B individuals

Stearate free encapsulation

Dr. Peter D'Adamo has identified dietary lectins (proteins found in many common foods) as an important influence of the body's immune system and metabolism. As a result of this research, he has designed specific 'lectin blocking' formulas to help support the body's immune system and metabolism.

This product contains no sugar, salt, gluten, wheat, yeast, corn, soy, eggs or dairy, no preservatives, color or flavors, and no artificial ingredients.

Product Details

DSLD Entry Date 2023-06-22
Product Type Other Combinations
Form Capsule
DSLD ID 287133
Data Updated 2026-04-11

Research Evidence

41 Research Sources
51 Avg Quality Score
19 Rct
13 Meta Analysis
9 Clinical Trial
B N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication
Meta Analysis The Cochrane database of systematic reviews 2019
B Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial
Rct Nature communications 2024
B N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure
Meta Analysis The Cochrane database of systematic reviews 2020
B Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
Meta Analysis European respiratory review : an official journal of the European Respiratory Society 2015
B A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo
Rct BMC medicine 2019
B Efficacy of N-acetylcysteine for patients with depression: An updated systematic review and meta-analysis
Meta Analysis General hospital psychiatry 2024
B Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates
Meta Analysis The Cochrane database of systematic reviews 2006
B N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials
Meta Analysis Bipolar disorders 2021
B N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials
Meta Analysis Psychopharmacology 2020
B N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses
Meta Analysis Archivos de bronconeumologia 2024
View all evidence for Nac →

Compare Similar Products

View all Nac products →